| GPC |
Report |
Operating EPS |
IN-LINE |
pred ~$2.06 vs. cons $2.07 |
MEDIUM |
| GPC |
Report |
Revenue |
IN-LINE |
pred ~$6.44B vs. cons $6.433B |
MEDIUM |
| GPC |
Report |
Total comparable-sales growth |
MISS |
pred ~2.8% vs. cons 2.9% |
MEDIUM |
| GPC |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide ~$7.50-$8.00 vs. cons $7.73 |
MEDIUM |
| GPC |
Guide |
FY26 total sales growth |
UNCHANGED |
guide ~3.0%-5.5% vs. cons FY sales $25.46B |
MEDIUM |
| GPC |
Guide |
Q3/Q4 margin and Iran-cost commentary |
UNKNOWN |
guide: Q2 cost trough / H2 improvement; no reliable numerical consensus |
LOW |
| GPC |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| GPC |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — in-line results and maintained FY guidance leave H2 estimates vulnerable |
LOW |